Showing results (1-10 of 335) with videos related to
Sort By:
Pageof 34
Nature Reviews. Clinical Oncology|March 26, 2014
Determining the optimal dose in the development of anticancer agentsRon H J Mathijssen, Alex Sparreboom, Jaap VerweijEuropean Journal of Cancer (Oxford, England : 1990)|December 6, 2005
Genotyping and phenotyping cytochrome P450: perspectives for cancer treatmentRon H J Mathijssen, Ron H N van SchaikCancer Treatment Reviews|January 26, 2015
Individualization of tamoxifen therapy: much more than just CYP2D6 genotypingLisette Binkhorst, Ron H J Mathijssen, Agnes Jager, et al.Current Cancer Drug Targets|August 22, 2002
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecanRon H J Mathijssen, Walter J Loos, Jaap Verweij, et al.The Oncologist|August 2, 2006
Complementary and alternative medicine during cancer treatment: beyond innocenceMetin Tascilar, Floris A de Jong, Jaap Verweij, et al.European Journal of Cancer (Oxford, England : 1990)|January 22, 2008
Lifestyle habits as a contributor to anti-cancer treatment failureFloris A de Jong, Alex Sparreboom, Jaap Verweij, et al.Investigational New Drugs|May 4, 2004
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patientsAlex Sparreboom, Sharon Marsh, Ron H J Mathijssen, et al.Clinical Pharmacology and Therapeutics|September 18, 2002
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrheaRujia Xie, Ron H J Mathijssen, Alex Sparreboom, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2002
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysisRujia Xie, Ron H J Mathijssen, Alex Sparreboom, et al.International Journal of Nanomedicine|November 2, 2020
Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of CancerRuben A G van Eerden, Ron H J Mathijssen, Stijn L W KoolenPageof 34